Opicapone in Early PD: Time to Revisit Off-Label COMT Use? 🔗 Access full article via Medscape NeurologyNew phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson’s disease, experts said. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
